98 related articles for article (PubMed ID: 1488335)
1. [Effectiveness of trimetazidine in patients with hypertension and the symptoms of coronary disease].
Kozakiewicz K; Petelenz T; Chruściel TL
Pol Tyg Lek; 1992 Jul 6-13; 47(27-28):594-6. PubMed ID: 1488335
[TBL] [Abstract][Full Text] [Related]
2. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo-controlled study.
Pornin M; Harpey C; Allal J; Sellier P; Ourbak P
Clin Trials Metaanal; 1994 Apr; 29(1):49-56. PubMed ID: 10150185
[TBL] [Abstract][Full Text] [Related]
3. The effects of trimetazidine on heart rate variability in patients with slow coronary artery flow.
Topal E; Ozdemir R; Barutcu I; Aksoy Y; Sincer I; Akturk E; Cehreli S
J Electrocardiol; 2006 Apr; 39(2):211-8. PubMed ID: 16580422
[TBL] [Abstract][Full Text] [Related]
4. [Captopril in the treatment of mild cardiac insufficiency in combination with arterial hypertension].
Ol'binskaia LI; Morozova TE
Ter Arkh; 1987; 59(4):103-6. PubMed ID: 3296282
[TBL] [Abstract][Full Text] [Related]
5. The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease.
Grabczewska Z; Białoszyński T; Szymański P; Sukiennik A; Swiatkiewicz I; Koziński M; Kochman W; Grześk G; Kubica J
Cardiol J; 2008; 15(4):344-50. PubMed ID: 18698543
[TBL] [Abstract][Full Text] [Related]
6. Discordance of anti-ischemic and hemodynamic effects of captopril in stable coronary artery disease.
Winkelmann BR; Matheis G; Kleist P; Pötter S; Wohltmann D; Kaltenbach M
Coron Artery Dis; 1994 Oct; 5(10):829-44. PubMed ID: 7866603
[TBL] [Abstract][Full Text] [Related]
7. [Clinical efficacy of combined therapy with enalapril + trimetazidine in patients with hypertension comorbid with ischemic heart disease and metabolic disturbances].
Petelina TI; Gapon LI; Bakhmatova IuA; Zhevagina IA
Ter Arkh; 2005; 77(8):19-23. PubMed ID: 16206600
[TBL] [Abstract][Full Text] [Related]
8. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefits of a metabolic approach in the management of coronary patients.
Marzilli M
Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V25-30. PubMed ID: 11206100
[TBL] [Abstract][Full Text] [Related]
10. [Value of trimetazidine in the long-term treatment of cardiomyopathies of ischemic origin].
Brottier L; Barat JL; Combe C; Boussens B; Bonnet J; Bricaud H
Ann Cardiol Angeiol (Paris); 1989 Mar; 38(3):179-82. PubMed ID: 2735733
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic and therapeutic effect of BAY a 1040 on the patients with ischemic heart disease.
Hayase S; Hirakawa S; Hosokawa S; Mori N; Kanyama S
Arzneimittelforschung; 1972 Feb; 22(2):370-3. PubMed ID: 4554632
[No Abstract] [Full Text] [Related]
12. [Effects of ketanserin on arterial pressure at rest and during physical exercise in essential arterial hypertension].
Gambini G; Gradoli C; Proietti MG; Pinchi G; Fioroni E; Valori C
Clin Ter; 1989 Jul; 130(2):101-7. PubMed ID: 2529082
[TBL] [Abstract][Full Text] [Related]
13. [Effect of trimitazidine on insulin resistance in patients with coronary heart disease].
Cai JS; Peng ZJ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):222-3, 226. PubMed ID: 16503536
[TBL] [Abstract][Full Text] [Related]
14. [Trimetazidine versus betahistine in vestibular vertigo. A double blind study].
Kluyskens P; Lambert P; D'Hooge D
Ann Otolaryngol Chir Cervicofac; 1990; 107 Suppl 1():11-9. PubMed ID: 2240994
[TBL] [Abstract][Full Text] [Related]
15. [Trimetazidine versus betahistine in Ménière's disease. A double blind method].
Martini A; De Domenico F
Ann Otolaryngol Chir Cervicofac; 1990; 107 Suppl 1():20-7. PubMed ID: 2240995
[TBL] [Abstract][Full Text] [Related]
16. Potassium magnesium supplementation for four weeks improves small distal artery compliance and reduces blood pressure in patients with essential hypertension.
Wu G; Tian H; Han K; Xi Y; Yao Y; Ma A
Clin Exp Hypertens; 2006 Jul; 28(5):489-97. PubMed ID: 16820345
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
18. [Clinical trial of the new coronary dilator hexobendine].
Henke C; Dudik E; Steim H
Arzneimittelforschung; 1968 Aug; 18(8):1103-7. PubMed ID: 4885101
[No Abstract] [Full Text] [Related]
19. Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance.
Leonardo F; Fragasso G; Rossetti E; Dabrowski P; Pagnotta P; Rosano GM; Chierchia SL
Cardiologia; 1999 Dec; 44(12):1065-9. PubMed ID: 10687257
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy of trimetazidine in cochleovestibular disorders of ischemic origin. A crossover control versus placebo trial].
Coyas A
Ann Otolaryngol Chir Cervicofac; 1990; 107 Suppl 1():82-7. PubMed ID: 2241007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
